Novartis Reports Phase 2 Data for Niraparib in Renal cell carcinoma

Novartis today announced Phase 2 results for niraparib in patients with renal cell carcinoma. The study demonstrated that niraparib reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of renal cell carcinoma and support the continued development of niraparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.